Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

BackgroundWe report the clinical activity, safety, and identification of a predictive biomarker for bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGFβRII (a TGF-β “trap”) fused to a human IgG1 mAb blocking PD-L1, in patients with advanced tripl...

Full description

Bibliographic Details
Main Authors: Alexander Spira, Ahmad Awada, Nicolas Isambert, David Lorente, Nicolas Penel, Yue Zhang, Laureen S. Ojalvo, Christine Hicking, P. Alexander Rolfe, Christian Ihling, Isabelle Dussault, George Locke, Christian Borel
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
bintrafusp alfa
triple-negative breast cancer
TGF-β
PD-L1
tumor microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.981940/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.981940/full

Similar Items